...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Modern Pathology >Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy
【24h】

Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy

机译：神经内分泌肿瘤中生长抑素受体2A型免疫组化：与生长抑素受体显像有关的评分系统的建议

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Typing somatostatin receptor expression in neuroendocrine tumors is of relevance to target somatostatin analogue-based diagnostic approach and treatment. The expanding use of immunohistochemistry to detect somatostatin receptors is to date not paralleled by an accurate methodological setting and standardized interpretation of the results. A multicentric study was designed to compare somatostatin receptor immunohistochemical expression with in vivo scintigraphic data and verify its usefulness in the clinical management of neuroendocrine tumors. After methodological setting by testing different somatostatin receptor antibodies, 107 cases of neuroendocrine tumors with available somatostatin receptor scintigraphy data and pathological material were retrospectively analyzed for somatostatin receptor types 2A, 3 and 5 immunohistochemical expression, and compared with scintigraphic images and, whenever available, with the clinical response to somatostatin analogue treatment. Restricting 'positive cases' to the presence of a membrane pattern of staining, an overall somatostatin receptor type 2A immunohistochemistry/somatostatin receptor scintigraphy agreement of 77% (2 test Pin vivo data, based on the evidence that only membrane (rather that cytoplasmic) staining should be considered for a reliable, standardized and clinically relevant report.
机译：在神经内分泌肿瘤中键入生长抑素受体的表达与基于靶生长抑素类似物的诊断方法和治疗有关。迄今为止，免疫组化技术在检测生长抑素受体方面的广泛应用尚无准确的方法论设置和结果的标准化解释。设计了一项多中心研究，以比较生长抑素受体免疫组织化学表达与体内闪烁显像数据，并验证其在神经内分泌肿瘤临床治疗中的有用性。在通过测试不同生长抑素受体抗体的方法学设置后，回顾性分析107例具有生长抑素受体闪烁显像数据和病理材料的神经内分泌肿瘤的生长抑素受体2A，3和5型免疫组织化学表达，并与闪烁显像图像进行比较，并在可能的情况下与生长抑素类似物治疗的临床反应。将“阳性病例”限制为存在染色的膜模式，总体2A型生长抑素受体免疫组织化学/生长抑素受体闪烁显像协议的一致性为77％（2测试Pin vivo数据，基于仅膜（而不是胞浆）的证据）应当考虑染色，以获得可靠，标准化和临床相关的报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号